• Wiley Online Library will be disrupted on 26 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance

Chapter 17. Clinical Progress in Tumor Vasculature-disrupting Therapies

  1. Dietmar W. Siemann2,3
  1. Andrew M. Gaya,
  2. Gordon J. S. Rustin

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch17

Book Title

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

Additional Information

How to Cite

Gaya, A. M. and Rustin, G. J. S. (2006) Clinical Progress in Tumor Vasculature-disrupting Therapies, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch17

Editor Information

  1. 2

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 3

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. Department of Medical Oncology, The Clocktower, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436

SEARCH

CHAPTER TOOLS

Get PDF (133K)

Keywords:

  • ligand-directed VDAs;
  • ‘targeted therapies’ to cancer cells;
  • clinical progress in tumor vasculature-disrupting therapies;
  • biological (ligand-directed) VDAs;
  • small-molecule VDAs;
  • Flavone acetic acid (FAA);
  • tubulin-binding agents;
  • Combretastatin A4;
  • CA4P dose-limiting toxicity (DLT);
  • potential surrogate markers of CA4P activity

Summary

This chapter contains sections titled:

  • Introduction

  • Potential clinical advantages of vascular-disrupting agents

  • Biological (ligand-directed) VDAs

  • Small-molecule VDAs

  • Potential surrogate markers of CA4P activity

  • Combination therapy with VDAs

  • VDAs in non-malignant diseases

  • Conclusions

  • References

Get PDF (133K)